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Abstract
Objectives To determine the incremental net health benefits of
dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in
patients with non-valvular atrial fibrillation and to estimate the cost
effectiveness of dabigatran in the United Kingdom.
Design Quantitative benefit-harm and economic analyses using a
discrete event simulation model to extrapolate the findings of the RE-LY
(Randomized Evaluation of Long-Term Anticoagulation Therapy) study
to a lifetime horizon.
Setting UK National Health Service.
Population Cohorts of 50 000 simulated patients at moderate to high
risk of stroke with a mean baseline CHADS2 (Congestive heart failure,
Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient
ischaemic attack) score of 2.1.
Main outcome measures Quality adjusted life years (QALYs) gained
and incremental cost per QALY of dabigatran compared with warfarin.
Results Compared with warfarin, low dose and high dose dabigatran
were associated with positive incremental net benefits of 0.094 (95%
central range −0.083 to 0.267) and 0.146 (−0.029 to 0.322) QALYs.
Positive incremental net benefits resulted for high dose dabigatran in
94% of simulations versus warfarin and in 76% of those versus low dose
dabigatran. In the economic analysis, high dose dabigatran dominated
the low dose, had an incremental cost effectiveness ratio of £23 082
(€26 700; $35 800) per QALY gained versus warfarin, and was more
cost effective in patients with a baseline CHADS2 score of 3 or above.
However, at centres that achieved good control of international
normalised ratio, such as those in the UK, dabigatran 150 mg was not
cost effective, at £42 386 per QALY gained.
Conclusions This analysis supports regulatory decisions that dabigatran
offers a positive benefit to harm ratio when compared with warfarin.
However, no subgroup for which dabigatran 110 mg offered any clinical
or economic advantage over 150 mg was identified. High dose dabigatran
will be cost effective only forpatients at increased risk of stroke or for
whom international normalised ratio is likely to be less well controlled.
Introduction
Atrial fibrillation is the most common sustained cardiac
arrhythmia,withanestimatedprevalenceintheUnitedKingdom
of 10% in patients aged 75 or over and an associated fivefold
increase in the risk of ischaemic stroke.
1 2 Bed days for patients
with a primary or secondary diagnosis of atrial fibrillation cost
the National Health Service (NHS) £1.9bn (€2.2bn; $2.9bn) in
2008,withoutpatientandotherinpatientcoststotalling£329m.
3
Warfarin is the mainstay of oral thromboprophylactic
anticoagulationtreatment.
4However,patientsshowconsiderable
variability in their response to warfarin, which, coupled with a
narrow therapeutic range, necessitates frequent monitoring and
adjustment of dosage to ensure optimal anticoagulation.
Deviations outside the therapeutic range (international
normalisedratio(INR)2.0-3.0)increasetheriskofbothstrokes
and haemorrhagic events.
5
Dabigatran etexilate is a new oral direct thrombin inhibitor that
may provide an alternative to warfarin; it has the advantage of
not requiring regular monitoring. In the multinational,
RandomizedEvaluationofLong-TermAnticoagulationTherapy
(RE-LY) study, 18 113 patients with non-valvular atrial
fibrillation and at least one risk factor for stroke were
randomised to one of two doses of dabigatran (110 mg or 150
mg, twice daily) or dose adjusted warfarin.
6 After a median
follow-upoftwoyears,theratesoftheprimaryoutcome(stroke
orsystemicembolism)weresimilartothoseforwarfarinamong
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RESEARCHpatientsassignedthelowerdosebutwereloweramongpatients
assigned the higher dose (1.11% v 1.71% per year; relative risk
0.66, 95% confidence interval 0.53 to 0.82; P=0.0001).
Compared with warfarin, the annual rate of major bleeding was
lower among patients assigned dabigatran 110 mg (2.71% v
3.36%; relative risk 0.80, 0.69 to 0.93; P=0.003) but similar
among those assigned 150 mg. Dabigatran was associated with
higher rates of myocardial infarction, but these were not
statistically significant.
7
The US Food and Drug Administration (FDA) was satisfied of
the positive benefit to harm balance of dabigatran but failed to
identifyasubgroupofpatientsinwhichthebenefit-harmprofile
was superior for the 110 mg dose compared with the 150 mg
doseandconsequentlyapprovedonlythehigherdose.
8However,
both doses have been approved by other regulatory authorities,
includingtheEuropeanMedicinesAgency,whichspecifies150
mg twice daily for patients under 80 years of age and 110 mg
twice daily for those aged 80 and over or as an option when the
thromboembolic risk is considered to be low and the risk of
bleeding is high.
9
Against this background, we describe a quantitative analysis of
the trade-off between thrombotic and bleeding risks—events
that have differential effects on life expectancy and quality of
life—asabasistoguideclinicians’prescribing.Wealsodevelop
a health economic evaluation to estimate the cost effectiveness
of dabigatran in patients with non-valvular atrial fibrillation,
given the considerable uncertainty about its cost effectiveness
in the UK healthcare setting.
Methods
We modelled the net benefits and expected lifetime clinical
event rates of each dose of dabigatran and warfarin to quantify
the benefits and harms of competing treatments, while
accounting for uncertainties in parameters.
10 11 We estimated
incremental net benefits as the difference between treatments
in quality adjusted life years (QALYs), a preference based
outcomemeasurethatcombinestwodimensionsofhealth—life
expectancy and health related quality of life.
In the economic analysis, we extended the model to estimate
resource use and costs from the perspective of the UK NHS.
The primary outcome was the incremental cost per QALY
gained.
We developed a discrete event simulation model that considers
individual patients, their characteristics, and their experience
of clinical events and outcomes according to the passage of
time.
12 After each event, a patient’s health profile is updated,
leadingtoanewsetofprobabilitiesforfutureevents.Costsand
QALYs are accrued from the patient’s health states and the
events that occur.
For each treatment, we generated identical cohorts of 50 000
patients, each assigned an age and health profile defined by the
presence/absence (according to the trial protocol
13) of any of
thefollowingcharacteristicsatbaseline:hypertension,diabetes
mellitus, congestive heart failure, previous stroke, previous
transient ischaemic attack, previous myocardial infarction, and
previous intracranial haemorrhage (table 1⇓).
6 We assumed
healthcharacteristicstobeindependentinthebasecaseanalysis
but did a sensitivity analysis to assess the effect of correlation.
We used R for all analyses.
Clinical parameter estimates
We searched Medline, Embase, the Cochrane library, and the
FDA and ClinicalTrials.gov websites during July 2010 to
identify relevant trials of dabigatran in atrial fibrillation. We
used “dabigatran,” “BIBR 1048,” and “atrial fibrillation” as
search terms and identified three phase II trials (PETRO,
26
PETRO-Ex,
14 and NCT01136408
14) and a single phase III trial
(RE-LY).
6 The phase II studies included too few patients
receiving the licensed dose and were of too limited a duration
(12 weeks) to provide useful data on reduction in stroke event
rate. The five year, open label extension to PETRO did not
includewarfarinasacomparator.WethereforeusedtheRE-LY
study for annualised clinical event rates (table 2⇓),
6 14 and the
patients modelled consequently represented those of RE-LY
(box 1).
Our analysis considered the probability of (and reasons for)
discontinuation of treatment to better reflect the “real world”
use of oral anticoagulants. At two years, this had occurred in
21% of patients randomised to dabigatran and 17% of those
randomised to warfarin.
6 14 We assumed that patients who
discontinueddabigatranbecauseofableedorwhodiscontinued
warfarin (for any reason) had been switched to aspirin. We
assumed that patients who discontinued dabigatran for reasons
other than bleeds were switched to warfarin, but we tested this
in a sensitivity analysis.
Incidence rates for hypertension and diabetes mellitus came
from general population data,
29 30 as did age specific mortality
rates from non-vascular causes,
31 all with the assumption that
these adequately reflect the RE-LY population (table 2⇓). The
relativerisksofthromboemboliceventsandbleedswithaspirin
(versus warfarin) came from a published meta-analysis of
comparative trials.
27 Box 2 lists key modelling assumptions.
Utility estimates
Wetookthepermanentutilitydecrementassociatedwithstroke
fromtheresultsoftheEuropeanStrokePreventionStudy,using
the proportions of disabling and non-disabling strokes from
RE-LY (45% of non-fatal strokes are non-disabling). The
baseline health state utility for a person with atrial fibrillation
(adjusted for age), as well as the decrements associated with
othercardiovascularsequelaeandhaemorrhagicadverseevents,
camefromareportofEQ-5Dutilityscoreselicitedfromseveral
thousand respondents to the US Medical Expenditure Panel
Survey.
15 17 Utility losses in patients receiving warfarin (for
example, as a consequence of regular monitoring) and aspirin
(assumed to be the same for dabigatran; for example, because
of gastrointestinal upset) came from a study of 83 patients with
atrial fibrillation.
16 Table 1 shows all utility values; multiple
utility decrements for an individual patient are assumed to be
additive.
Resource use and cost estimates
All costs (besides those of dabigatran) are reported in 2009
GBP(£). We inflated costs incurred during the first and
subsequent years after stroke or myocardial infarction from
2006/7 prices.
18 Costs included in this figure were ward costs
(staffing, equipment, consumables, and overheads) and
procedurecosts(whichalsoincludedthecostofhospitaldrugs),
inpatient and outpatient costs, costs of general practitioners’
and district nurses’ visits, and the costs of other drugs.
18 The
costsofpulmonaryemboliandtransientischaemicattackscame
from NHS reference costs,
19 as did those for managing major
and minor bleeds, following the methods and definitions of a
report by the National Institute for Health and Clinical
Excellence (NICE) on the costing of atrial fibrillation.
20
Incidences of other adverse events did not differ significantly
between treatment groups, so we did not deem attaching a cost
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RESEARCHBox 1: Population modelled
The population modelled reflected patients in the RE-LY study,
6 who were 63.6% male and 70% white, with a mean age of 71.5 years, a
mean weight of 82.6 kg, and no contraindication to anticoagulation. Mean baseline CHADS2 (Congestive heart failure, Hypertension, Age≥75
years, Diabetes mellitus, previous Stroke/transient ischaemic attack) score was 2.1, and 32.4% of patients had a score of 3 or more; 50.4%
of patients were naive to vitamin K antagonists.
Box 2: Assumptions made in constructing model
• The risk of future cardiovascular events for each simulated patient, at any given time, is determined by their age, current treatment,
and CHADS2 score (a stroke risk index based on age, diagnosis of hypertension, diabetes or congestive heart failure, and previous
stroke or transient ischaemic attack,
34) according to probabilities determined from RE-LY (table 2⇓)
• Clinical event rates (including for myocardial infarction) would remain constant over time, unless a change occurred in one or more
of the risk factors
• The rates of discontinuation of treatment in the second year of the RE-LY study persisted for the lifetime of treatment
• The incidence (though not the prevalence) of hypertension and diabetes was the same in patients with atrial fibrillation as in the general
population, as were deaths from non-vascular causes
tosucheventstobenecessary.Theexceptiontothisisthehigher
incidence of dyspepsia in the dabigatran groups—11.8% for
110 mg and 11.3% for 150 mg, compared with 5.8% for
warfarin—which we accounted for by including the cost of
protonpumpinhibitors.Theproportionofpatientstakingproton
pumpinhibitorscamefromRE-LY,andthenumberofcapsules
per patient came from a published cost effectiveness analysis.
21
Therelativeproportionofpatientsusingprotonpumpinhibitors
in conjunction with aspirin came from a randomised controlled
trial of antithrombotic treatments.
28
We based the costs of warfarin and associated monitoring on a
micro-costing analysis of 165 patients with atrial fibrillation
included in a six month prospective cohort study, with the cost
of starting warfarin excluded from the long term maintenance
cost.
22 The average use of aspirin in practice came from a
published costing study.
32
Drug acquisition costs came from the British National
Formulary and the NICE appraisal consultation document for
dabigatran.
23 24 Table 1⇓ shows all costs.
Discounting
We applied an annual discount rate of 3.5% to costs, life years,
andQALYstoreflecttimepreferencebutnottodiscreteclinical
events.
25 33
Age adjusted dosing
In age adjusted dosing, patients initially below the age of 80
years start on the 150 mg dose of dabigatran, and those aged 80
or above start on the 110 mg dose. If a person reaches 80 and
is still continuing with the 150 mg dose, he or she is then
switched to the 110 mg dose. We modelled this regimen in two
different ways. Our primary method used the results of a post
hoc subgroup analysis,
14 which subdivided people by age. The
secondary method used the event rates from the full trial for
patients taking either dose.
Sensitivity and scenario analyses
We did univariate sensitivity analyses of each parameter in the
modeltoassessthestabilityoftheresultswhenkeyassumptions
are tested. We based ranges for parameters on 95% confidence
intervals where available, or, alternatively, on plausible
percentageranges(webextratableA).Wetestedthepossibility
that the cost of managing intracranial haemorrhage and
gastrointestinal bleeding may be higher with dabigatran than
with warfarin, because of the lack of an appropriate reversal
agent, by increasing the costs to consider the potential use of
prothrombin complex concentrates (non-activated or
activated).
35 36
Our base case assumes that the benefit of treatment persists for
the lifetime of patients. We tested two further scenarios: one in
which the benefit persisted for two years and a second in which
the benefit decreased linearly to zero over the 10 years after the
trial.
We did a probabilistic sensitivity analysis, implementing a
Monte Carlo simulation of 2000 sets of simulated parameters
(table1⇓,webextratableB),toestimatethe95%centralranges
for clinical event rates and net health benefits. In the economic
analysis, we used the probabilistic sensitivity analysis to
consider the joint uncertainty in costs and QALYs to estimate
the probabilities of dabigatran being cost effective at different
thresholds,presentedasacosteffectivenessacceptabilitycurve,
and in different clinical scenarios.
We did subgroup analyses to calculate the net health benefits
(and associated 95% central ranges), the incremental cost
effectiveness ratios, and the probability of cost effectiveness,
in the following pre-specified populations
14 37-39: patients aged
75 or older; patients with a CHADS2 (Congestive heart failure,
Hypertension, Age≥75 years, Diabetes mellitus, previous
Stroke/transient ischaemic attack) score of 2, or a CHADS2
score of 3 or more; patients who have previously had a stroke
or transient ischaemic attack; patients attending trial centres
(clinics) reporting mean INR time within the therapeutic range
of more (or less) than 65.5%; patients on warfarin whose time
within the therapeutic range was more (or less) than 66.8%,
compared with the full dabigatran populations (only summary
information was available for this calculation); patients with
poor renal function as indicated by a low (30-50 mL/min)
creatinine clearance; and patients who were naive to vitamin K
antagonist treatment.
Results
The results of our simulation at two years matched the results
of the trial. No value deviated by more than 2.1% (data not
shown), a level of variability that would be expected given the
stochastic nature of the simulation.
Clinical outcomes and net health benefit
In the base case analysis, dabigatran 110 mg and 150 mg twice
daily extended life by 1.1 and 2.4 months compared with
warfarin(table3⇓).Thecorrespondingincrementalnetbenefits
were 0.094 (95% central range −0.083 to 0.267) and 0.146
(−0.029 to 0.322) QALYs. Compared with the low dose of
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RESEARCHdabigatran, the higher dose was associated with a positive
incremental net benefit in 76% of simulations and with a mean
value of 0.052 (−0.122 to 0.228) QALYs. Compared with
warfarin, dabigatran 110 mg and 150 mg twice daily were
associated with positive incremental net benefits in 86% and
94% of simulations.
Lifetimeincidencesofstrokeorsystemicembolismwere12.5%
lower with dabigatran 110 mg twice daily than with warfarin
and27.4%lowerwithdabigatran150mgtwicedaily.Incidences
of major haemorrhagic events were lower for low dose
dabigatran (by 4.0%) but higher for high dose dabigatran (by
8.8%). We found no discernible differences in lifetime
incidences of myocardial infarction between the two doses of
dabigatran, but these were about 19% higher than for warfarin.
Although age adjusted dabigatran dosing was associated with
lower bleeding rates, the higher rates of thrombotic events
resulted in it being inferior to the 150 mg dose with respect to
QALYs and life years gained.
Costs and cost effectiveness
Total discounted lifetime costs for dabigatran 110 mg and 150
mg twice daily and warfarin were £10 529, £9850, and £6480.
Theseweremadeupmainlyofdrugandmonitoringcosts,which
accounted for 47.3% and 44.2% of the overall costs of the two
doses of dabigatran compared with 22.4% for warfarin. The
costs of managing strokes or systemic emboli accounted for
39.1%, 40.2%, and 57.6% of total costs; the remainder was
accounted for by the costs of managing other events.
The incremental cost effectiveness ratio (ICER) for low dose
dabigatranversuswarfarinwas£43074perQALYgained;that
for high dose dabigatran was £23 082 per QALY gained (table
4⇓).Dabigatran110mgtwicedailywasdominatedasastrategy
by dabigatran 150 mg twice daily, as it was associated with a
worsehealthoutcome(−0.052QALYs)andhighercost(£679).
Age adjusted dosing
The use of dabigatran 110 mg twice daily from the age of 80
yearswasdominatedbythe150mgtwicedailydoseunderboth
possible modelling methods. In the models based on the post
hoc subgroup analysis and using full RE-LY data, the use of
the lower dose accrued 0.005 and 0.017 fewer QALYs and cost
£62 and £234 more over a lifetime. Compared with warfarin,
the ICERs for use of low dose dabigatran in the over-80s were
£24 340 and £27 940 per QALY gained for the two methods.
Sensitivity analysis
Thetornadoplot(fig1⇓)indicatesthesensitivityofincremental
net benefits to stroke rates and the duration of effect of
dabigatran. Dabigatran 150 mg twice daily was cost effective
at the lower threshold of £20 000 per QALY when we assumed
decreases (or increases) in the rates of stroke or vascular death
in patients receiving dabigatran (or warfarin) or increases in
either clinical event costs or utility losses. Compared with
warfarin,theICERfordabigatran110mgtwicedailyexceeded
£32 415 per QALY in all sensitivity analyses (data not shown).
The probabilistic sensitivity analysis (fig 2⇓) indicates that
warfarin had the highest probability of being cost effective at
thresholds of £24 400 or lower. Dabigatran 150 mg twice daily
was the most probable cost effective option at thresholds above
thatvalue.Consideringapair-wisecomparisonbetweenwarfarin
and dabigatran 150 mg twice daily, warfarin was the most cost
effective treatment at thresholds of £22 800 and below.
Subgroup analyses
Amongthesubgroupsanalysed,themeanincrementalnethealth
benefit consistently favoured both doses of dabigatran over
warfarin and dabigatran 150 mg twice daily over 110 mg twice
daily (fig 3⇓).
Dabigatran 150 mg twice daily was within the £30 000 per
QALYcosteffectivenessthresholdforallsubgroupsofpatients
other than in centres with mean time within the therapeutic
range for INR of at least 65.5% (table 4⇓). Dabigatran 150 mg
twice daily was most cost effective in patients at high risk of
stroke (CHADS2 score ≥3), but even here the probability of it
being cost effective was only 68%. Dabigatran 110 mg twice
daily, when used for all ages or restricted to patients aged 80 or
over, was dominated by the higher dose in all subgroups (data
not shown).
Discussion
Our quantitative benefit-harm analysis found that dabigatran
wasassociatedwithpositivenethealthbenefitswhencompared
with warfarin. High dose dabigatran was the most clinically
effective option. Greatest benefits were evident in patients in
whom control of INR is poorest (patients’ time within the
therapeutic range <66.8%) and fewest benefits in centres that
achievegoodINRcontrol(centretimewithintherapeuticrange
≥65.5%). We were unable to identify a subgroup of patients in
which the lower dose of dabigatran—when used for all ages or
restrictedtopatientsaged80orover—wassuperiortothehigher
dose.Thebenefitsofreducedbleedingrateswiththelowerdose
were offset by reduced efficacy in preventing stroke. These
findingsareinaccordancewiththeresultsoftheRE-LYstudy,
6
and related subgroup analyses,
14 37-39 and lend support to the
FDA’s rationale for not licensing the 110 mg dose.
8
The economic analysis indicated that for the overall RE-LY
study population, dabigatran 150 mg twice daily is potentially
a cost effective alternative to warfarin, at £23 082 per QALY
gained. However, its probability of being cost effective at a
threshold of £20 000 per QALY is only 45%. This uncertainty
is driven largely by rates of stroke and, to a lesser extent,
vasculardeathandthecostofmanagingstrokes.NICE’scriteria
for decision making state that “above a most plausible ICER of
£20,000 per QALY gained, judgements about the acceptability
of the technology as an effective use of NHS resources will
specifically take account of . . . the degree of certainty around
the ICER. . . NICE will be more cautious about recommending
atechnologywhenitislesscertainabouttheICERspresented.”
25
Dabigatran 110 mg twice daily is not a cost effective option,
and the age adjusted dosing regimen was dominated in all
scenarios by the 150 mg dose.
High dose dabigatran was more cost effective in patients at a
greater risk of stroke (baseline CHADS2 score ≥3). However,
at centres that achieve good INR control (centres’ time within
therapeutic range ≥65.6%), dabigatran 150 mg twice daily is
nolongercosteffective,at£42386perQALYgained.Although
the mean time within the therapeutic INR range in the UK of
72%intheRE-LYstudymaybehigherthanroutinepractice,
22 37
sotoomightadherencetodabigatran,whichrequirestwicedaily
dosing compared with warfarin’s once.
Comparison with other studies
We are not aware of any quantitative benefit-harm analyses of
dabigatran in atrial fibrillation. However, two economic
evaluationsofdabigatraninnon-valvularatrialfibrillationhave
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cost effectiveness on the basis of the RE-LY trial.
TheUSstudy,whichadoptedthecostingperspectiveofahealth
insurer,
40 yielded a quality adjusted life expectancy of 10.28
with warfarin, 10.70 with low dose dabigatran, and 10.84 with
high dose dabigatran. These are considerably higher than our
estimates, primarily because of patients’ starting age which, at
65 years, was 6.1 years younger than in our analysis based on
the RE-LY population. Nevertheless, despite this difference,
similarresultswereobtainedwithrespecttodabigatran150mg
twicedailybeingassociatedwithpositiveincrementalnethealth
benefits across a range of risks for stroke and intracranial
haemorrhage, compared with dabigatran 110 mg twice daily
and warfarin. A similar economic outcome also resulted; the
ICER fell just below the cost effective threshold but had a high
level of uncertainty, driven mostly by drug costs and stroke
rates.
The Canadian study,
41 sponsored by the manufacturer of
dabigatran and based on RE-LY patient level data (though not
listedasapre-specifiedanalysis),
13assesseditscosteffectiveness
accordingtothesameageadjusteddosingscheduleasapproved
in Europe. In contrast to the US study and our study, however,
dabigatran was deemed to be cost effective compared with
warfarin, at $C10 440 (£6466; €7468; $10 026) per QALY
gained. Differences relate largely to costs, which were
proportionally much greater for the management of events and
long term care in the Canadian analysis. Considering a patient
taking dabigatran who has an acute stroke and five years of
follow-up costs, in our analysis the cost of stroke is about five
times higher than the cost of drugs whereas in the Canadian
study it is more than 15 times higher.
Strengths and weaknesses
Our analysis benefited from application of a discrete event
simulationmethod,whichisthemethodofchoiceforconditions
in which no obvious discrete disease states exist into which
patients can be classified, a necessary assumption for a Markov
model.
12 It allows for a much larger number of potential health
states to be modelled and removes the need to define the
additional structural parameters necessary for a Markov model
(suchascyclelength).Adiscreteeventsimulationalsooperates
in continuous rather than discrete time, thus more naturally
approximatingactualpatients’historiesandallowingcontinuous
parameters (such as age) to be more appropriately modelled.
Our analysis counters the concerns raised by NICE in its
appraisal of the manufacturer’s submission,
24 through the
inclusion of the age adjusted dosing regimen, use of reliable
estimates of INR monitoring cost, continuation of dyspepsia
throughout the duration of dabigatran treatment, and
independencefromtreatmentoftherisksofdisabilityanddeath
after stroke. We had no access to data on the quality of life
sub-study of RE-LY, and we made no attempt at modelling a
typical UK population with atrial fibrillation, who are typically
older, with proportionately more women, and have a different
riskprofileforstrokethantheRE-LYtrialpopulation.
42Patients
are also less likely to persist with anticoagulant treatment in
routine practice than in a clinical trial setting,
42 but we had no
additional data for more elaborate modelling.
43
Several caveats exist. Firstly, the reliance on the RE-LY study
asthesolesourceofclinicaldataisapotentialcauseforconcern.
AlthoughRE-LYisoneofthelargesttrialsofatrialfibrillation,
this makes assessing the effect of any possible weaknesses in
the design of the RE-LY study difficult (for example, its open
label design, a significant proportion of patients taking aspirin
concomitantly,andonlyaboutathirdofpatientswithabaseline
CHADS2 score ≥3). We were further limited by not having
access to data for individual patients. Our a priori decision to
base our analysis on the entire RE-LY study population may
limit the generalisability of the base case estimates to a UK
context. Subgroups, defined by centres achieving better INR
control and patients in the higher categories of risk for stroke,
may result in more relevant estimates of ICER.
Secondly, the necessity of bringing together data from a wide
variety of sources has the potential to introduce bias into the
analysis. For example, relative event rates for aspirin treatment
came from a separate study, which will have had different
demographics and different warfarin dosing schedules from
RE-LY. Extrapolation of a two year trial to a lifetime horizon
also raises questions, as does the assumption that utility
decrements for events derived from the general population are
appropriate for patients with atrial fibrillation. However,
approximations such as these are unavoidable in economic
modelling. Thirdly, we did not include the possibility that
widespread use of dabigatran might affect the provision of
anticoagulation clinic services, as we considered displacement
of warfarin by dabigatran to such an extent to be unlikely.
Implications for practice and future research
Dabigatran has advantages over warfarin; the most important
are that monitoring is not needed, that anticoagulation for a
given dose is more predictable, and that fewer drug-drug
interactions are likely. However, it also has disadvantages.
44
Firstly, the lack of monitoring provides little ability to
objectively monitor adherence, which in the real world setting
is likely to be worse with dabigatran given the need for twice
daily dosing and its associated higher incidence of dyspepsia.
Secondly, ifthe patient has aserious bleed, no provenantidotes
exist.
45 Thirdly, some uncertainty exists about dosing in certain
clinical settings such as renal failure, old age, and concomitant
intake of amiodarone, which may lead to either underdosing or
overdosing given that no pharmacodynamic marker for
monitoringexists.Fourthly,thesafetyandefficacyofthrombin
inhibitors in the longer term (beyond two years) are uncertain,
although the follow-up study of RE-LY patients should yield
valuable information.
46
Animportantfindingfromthecosteffectivenessanalysisisthat
dabigatranisnotcosteffectivewhencomparedinpatientswhose
INR is well controlled or in centres that achieve good INR
control.Partofthereasonforsuchvariabilityinthetimewithin
the therapeutic range with warfarin is the presence of genetic
polymorphismsintheCYP2C9andVKORC1genes.
22 47Atleast
four randomised trials are running globally in which genotype
guided prescribing of warfarin, which is predicted to improve
the time within the therapeutic range, is being tested against
currentclinicalcare.Whetherdabigatranwouldbecosteffective
against genotype guided prescribing of warfarin is unclear and
needs further evaluation. Furthermore, other competitors to
dabigatran are due to be evaluated for licensing soon, such as
rivaroxaban and apixaban, which have shown similar clinical
effectiveness to warfarin but have not been tested against
dabigatran.
48 Thus, although the arrival of new anticoagulants
should be welcomed, their place in the prevention of strokes in
patients with atrial fibrillation in comparison with warfarin
(perhaps genotype guided) needs further evaluation. In the end,
a stratified approach may represent the best approach to
maximise both the clinical effectiveness and cost effectiveness
of anticoagulation in patients with atrial fibrillation.
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RESEARCHWhat is already known on this topic
Dabigatran etexilate is an alternative thromboprophylactic agent to warfarin for patients with non-valvular atrial fibrillation
However, uncertainty exists about its dose, balance of benefits and harms, and cost effectiveness
Previous cost effectiveness analyses of dabigatran for this indication have shown conflicting results and have not used appropriate
modelling approaches
What this study adds
Dabigatran was associated with positive incremental net benefits versus warfarin, but dabigatran 110 mg twice daily did not offer clinical
or economic advantage over 150 mg twice daily in any subgroup
Dabigatran is unlikely to be cost effective in clinics, such as those in the UK, able to achieve good control of the international normalised
ratio (INR) with warfarin
Dabigatran 150 mg twice daily, and an age adjusted dosing regimen, will be cost effective only for patients at increased risk of stroke
or for whom INR is likely to be less well controlled
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RESEARCHTables
Table 1| Patients’ baseline characteristics, costs, health state utilities, and discount rate parameters used in model
References Probabilistic sensitivity analysis distribution Value Parameter
Baseline characteristics*
6, 14 β (14 283, 3830) 14 283/18 113 Hypertension
6, 14 β (4221, 13 892) 4221/18 113 Diabetes
6, 14 β (5793, 12 320) 5793/18 113 Heart failure
6, 14 β (2273, 15 840) 2273/18 113 Previous stroke
6, 14 β (1663, 16 450) 1663/18 113 Previous transient ischaemic attack
6, 14 β (3005, 15 108) 3005/18 113 Previous myocardial infarction
6, 14 β (713, 17 400) 713/18 113 Previous intracranial haemorrhage
Health state utilities
15 1−γ (43.06, 0.0052) 0.774 Atrial fibrillation (age 67)
16 Normal (0.233, 0.0032) 0.233 Stroke (permanent disutility)†
15, 17 Normal (0.1385, 0.01) 0.1385 Stroke (temporary disutility)†
17 Uniform (0, 0.183) 1/12 Stroke (temporary duration, years)†
15 Normal (0.0409, 0.002) 0.0409 Myocardial infarction (permanent disutility)
15, 17 Normal (0.1247, 0.01) 0.1247 Myocardial infarction (temporary disutility)
17 Uniform (0, 0.183) 1/12 Myocardial infarction (temporary duration, years)
15 Normal (0.0524, 0.001) 0.0524 Intracranial haemorrhage (permanent disutility)
15, 17 Normal (0.1385, 0.01) 0.1385 Pulmonary embolism (temporary disutility)
17 Uniform (0, 0.183) 1/12 Pulmonary embolism (temporary duration, years)
15, 17 Normal (0.1032, 0.01) 0.1032 Transient ischaemic attack (temporary disutility)
17 Uniform (0, 0.027) 5/365 Transient ischaemic attack (temporary duration, years)
15, 17 Normal (0.1385, 0.01) 0.1385 Major bleed (temporary disutility)
17 Uniform (0, 0.183) 1/12 Major bleed (temporary duration, years)
17 Normal (0.06, 0.01) 0.06 Minor bleed (temporary disutility)
17 Uniform (0, 0.027) 5/365 Minor bleed (temporary duration, years)
16 γ (1.3, 0.01) 0.013 Warfarin disutility
Assumption γ (0.2, 0.01) 0.002 Dabigatran disutility
16 γ (0.2, 0.01) 0.002 Aspirin disutility
Costs
18 γ (102.68, 102.68) £10 543.36 Stroke—year 1†
18 γ (52.74, 52.74) £2781.22 Stroke—subsequent years†
18 γ (58.26, 40.46) £2357.13 Myocardial infarction—year 1
18 γ (34.55, 23.99) £828.90 Myocardial infarction—subsequent years
19 NA £1543.27 Pulmonary embolism
19 NA £839.62 Transient ischaemic attack
20 NA £1684.58 Major bleed
20 NA £93.17 Minor bleed
21 NA £185.20 Proton pump inhibitors (1 year)
22, 23 Uniform (32.98,49.48) £41.23 Warfarin—drugs (1 year)
22 γ (202.59, 0.979) £198.39 Warfarin—monitoring (1 year)
24 NA £919.80 Dabigatran—both doses (1 year)
17, 23 γ (73.9, 0.1) £7.39 Aspirin (1 year)
Discount rate
25 NA 3.5% Utilities
25 NA 3.5% Costs
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RESEARCHTable 1 (continued)
References Probabilistic sensitivity analysis distribution Value Parameter
NA=not applicable.
*Proportion in initial population.
†Includes both strokes and systemic emboli, excluding pulmonary emboli.
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RESEARCHTable 2| Clinical parameters used in model
References Dabigatran 150 mg Dabigatran 110 mg Warfarin Aspirin Parameter*
Clinical event rates
6, 14, 27 0.0068 0.0112 0.0109 0.0177 Stroke (CHADS2 score ≤1)†‡
6, 14, 27 0.0084 0.0145 0.0138 0.0222 Stroke (CHADS2 score 2)†‡
6, 14, 27 0.0189 0.0212 0.0273 0.0441 Stroke (CHADS2 score ≥3)†‡
6, 14, 27 0.0015 0.0012 0.0010 0.0016 Pulmonary embolism†
6, 14, 27 0.0072 0.0062 0.0084 0.0135 Transient ischaemic attack†
6, 14 0.0048 0.0070 0.0062 0.0062 Congestive heart failure†
6, 14 0.1887 0.1887 0.1887 0.1887 Probability of death from stroke‡
6, 14 0.1591 0.1591 0.1591 0.1591 Probability of death from pulmonary
embolism
6, 14 0.0208 0.0216 0.0228 0.0228 Vascular death (excluding stroke and
systemic and pulmonary embolism)†
6, 14 0.0960 0.0839 0.2191 0.2191 Probability that major bleed is intracranial
haemorrhage
Adverse events
6, 14, 27 0.0220 0.0188 0.0290 0.0127 Major bleed (CHADS2 score ≤1)†
6, 14, 27 0.0304 0.0298 0.0331 0.0145 Major bleed (CHADS2 score 2)†
6, 14, 27 0.0486 0.0380 0.0461 0.0202 Major bleed (CHADS2 score ≥3)†
6, 14, 27 0.1485 0.1316 0.1637 0.0718 Minor bleed†
6, 14 0.4725 0.4596 0.4600 NA Non-bleed adverse events
6, 14, 28 0.2164 0.2126 0.1840 0.2317 Proportion of patients using proton pump
inhibitor
6, 14, 18 0.0081 0.0082 0.0064 0.0064 Myocardial infarction†
Comorbidities
29 0.0122 0.0122 0.0122 0.0122 Diabetes†
30 0.0271 0.0271 0.0271 0.0271 Hypertension†
Discontinuations
6, 14 0.2133 0.1801 0.1425 NA Probability that major bleed leads to
discontinuation
6, 14 0.0292 0.0298 0.0194 NA Probability that adverse event leads to
discontinuation
6, 14 0.1226 0.1160 0.0832 NA Probability that discontinue year 1 (other
reasons)
6, 14 0.0432 0.0475 0.0459 NA Probability that discontinue year 2 onwards
(other reasons)
CHADS2=Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack; NA=not applicable.
*See web extra table B for parameters specifying distributions for probabilistic sensitivity analysis.
†Presented as rates per 100 person years.
‡Includes both strokes and systemic emboli but not pulmonary emboli.
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RESEARCHTable 3| Lifetime estimates of event rates, net benefits, and incremental differences versus comparator, derived from probabilistic sensitivity
analysis
Comparator Mean (95% central range) difference* Mean (95% central range) estimate Referent
Quality adjusted life years (QALYs)†
Dabigatran 110 mg bid −0.094 (0.083 to −0.267) 6.390 (6.265 to 6.517) Warfarin
Dabigatran age adjusted‡ −0.049 (0.126 to −0.221) 6.484 (6.360 to 6.634) Dabigatran 110 mg bid
Dabigatran 150 mg bid −0.005 (0.171 to −0.180) 6.531 (6.401 to 6.664) Dabigatran age adjusted‡
Warfarin 0.146 (−0.029 to 0.322) 6.536 (6.413 to 6.662) Dabigatran 150 mg bid
Life years†
Dabigatran 110 mg bid −0.089 (0.142 to −0.323) 10.851 (10.687 to 11.018) Warfarin
Dabigatran age adjusted‡ −0.102 (0.129 to −0.338) 10.940 (10.776 to 11.111) Dabigatran 110 mg bid
Dabigatran 150 mg bid −0.009 (0.243 to −0.232) 11.042 (10.873 to 11.221) Dabigatran age adjusted‡
Warfarin 0.200 (−0.035 to 0.429) 11.051 (10.885 to 11.220) Dabigatran 150 mg bid
Stroke or systemic embolism (excluding pulmonary emboli)
Dabigatran 110 mg bid 0.0302 (−0.0260 to 0.0875) 0.2408 (0.2010 to 0.2841) Warfarin
Dabigatran age adjusted‡ 0.0308 (−0.0268 to 0.0893) 0.2107 (0.1698 to 0.2538) Dabigatran 110 mg bid
Dabigatran 150 mg bid 0.0044 (−0.0476 to 0.0511) 0.1799 (0.1401 to 0.2245) Dabigatran age adjusted‡
Warfarin −0.0654 (−0.0092 to −0.1226)§ 0.1755 (0.1354 to 0.2196) Dabigatran 150 mg bid
Ischaemic stroke
Dabigatran 110 mg bid −0.0045 (−0.0565 to 0.0493) 0.1718 (0.1484 to 0.1982) Warfarin
Dabigatran age adjusted‡ 0.0331 (−0.0189 to 0.0822) 0.1763 (0.1507 to 0.2067) Dabigatran 110 mg bid
Dabigatran 150 mg bid 0.0044 (−0.0502 to 0.0570) 0.1432 (0.1167 to 0.1708) Dabigatran age adjusted‡
Warfarin −0.0330 (0.0261 to −0.0803) 0.1388 (0.1121 to 0.1662) Dabigatran 150 mg bid
Transient ischaemic attack
Dabigatran 110 mg bid 0.0218 (−0.0280 to 0.0712) 0.1643 (0.1281 to 0.2074) Warfarin
Dabigatran age adjusted‡ 0.0273 (−0.0237 to 0.0762) 0.1425 (0.1057 to 0.1791) Dabigatran 110 mg bid
Dabigatran 150 mg bid 0.0042 (−0.0449 to 0.0580) 0.1152 (0.0791 to 0.1509) Dabigatran age adjusted‡
Warfarin −0.0533 (−0.0035 to −0.1027)§ 0.1110 (0.0744 to 0.1476) Dabigatran 150 mg bid
Intracranial haemorrhage
Dabigatran 110 mg bid 0.0479 (0.0347 to 0.0614)§ 0.0756 (0.0655 to 0.0835) Warfarin
Dabigatran age adjusted‡ −0.0062 (−0.0191 to 0.0077) 0.0277 (0.0240 to 0.0308) Dabigatran 110 mg bid
Dabigatran 150 mg bid −0.0017 (−0.0133 to 0.0116) 0.0339 (0.0298 to 0.0372) Dabigatran age adjusted‡
Warfarin −0.0400 (−0.0271 to −0.0578)§ 0.0356 (0.0322 to 0.0391) Dabigatran 150 mg bid
Major bleed (including intracranial haemorrhage)
Dabigatran 110 mg bid 0.0133 (−0.0409 to 0.0673) 0.3313 (0.2942 to 0.3766) Warfarin
Dabigatran age adjusted‡ −0.0379 (−0.0902 to 0.0257) 0.3180 (0.2811 to 0.3623) Dabigatran 110 mg bid
Dabigatran 150 mg bid −0.0048 (−0.0561 to 0.0512) 0.3559 (0.3180 to 0.3985) Dabigatran age adjusted‡
Warfarin 0.0294 (0.0835 to −0.0247) 0.3607 (0.3233 to 0.4017) Dabigatran 150 mg bid
Non-fatal myocardial infarction
Dabigatran 110 mg bid −0.0109 (−0.0346 to 0.0126) 0.0612 (0.0434 to 0.0813) Warfarin
Dabigatran age adjusted‡ −0.0006 (−0.0251 to 0.0256) 0.0721 (0.0560 to 0.0895) Dabigatran 110 mg bid
Dabigatran 150 mg bid −0.0003 (−0.0250 to 0.0255) 0.0727 (0.0560 to 0.0914) Dabigatran age adjusted‡
Warfarin 0.0119 (0.0356 to −0.0116) 0.0730 (0.0561 to 0.0934) Dabigatran 150 mg bid
bid=twice daily.
*Difference from comparator group.
†Discounted at 3.5% per annum.
‡Age adjusted dabigatran dosing regimen (110 mg bid for patients aged ≥80 years) based on post hoc subgroup analysis.
§95% central range for incremental difference does not cross zero.
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RESEARCHTable 4| Cost effectiveness results for subgroups, based on probabilistic sensitivity analysis
Probability of cost effectiveness*
ICER (£/QALY)
Dabigatran 150
mg bid QALYs
Dabigatran 150
mg bid cost (£)
Warfarin
QALYs
Warfarin cost
(£) Subgroup
At £30 000 per
QALY
At £20 000 per
QALY
0.596 0.449 23 082 6.536 9850 6.390 6480 RE-LY population
0.615 0.475 20 207 6.433 10 443 6.283 7412 CHADS2 score 2
0.683 0.565 15 895 6.396 12 646 6.224 9912 CHADS2 score ≥3
0.309 0.137 42 386 6.605 9977 6.517 6247 Centres’ time in therapeutic
range ≥65.5%
0.636 0.469 20 396 6.410 9656 6.261 6617 Centres’ time in therapeutic
range <65.5%
0.511 0.393 26 281 6.536 9850 6.401 6302 Patients’ time in therapeutic
range ≥66.8%
0.643 0.519 17 932 6.536 9850 6.360 6694 Patients’ time in therapeutic
range <66.8%
0.631 0.501 18 647 6.460 10 788 6.310 7991 Creatinine clearance <30-50
mL/min
0.649 0.525 17 286 6.378 12 787 6.217 10 004 Previous stroke or transient
ischaemic attack
0.587 0.446 22 517 6.545 9792 6.396 6437 Vitamin K antagonist naive
0.635 0.498 17 857 4.429 7362 4.275 4612 Age ≥75 years
bid=twice daily; CHADS2=Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack; ICER=incremental
cost effectiveness ratio; QALY=quality adjusted life year; RE-LY=Randomized Evaluation of Long-Term Anticoagulation Therapy.
*Proportion of simulations in which dabigatran 150 mg twice daily is cost effective versus warfarin.
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RESEARCHFigures
Fig 1 Tornado plot of univariate sensitivity analyses. First three panels relate to benefit-harm analyses; lower right panel
relates to economic comparison of dabigatran 150 mg twice daily and dose adjusted warfarin. L=lower end of 95% CI for
parameter set; H=higher end of 95% CI for parameter set (see web extra table A). bid=twice daily; CHADS2= Congestive
heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack; ICER=incremental
cost effectiveness ratio; QALY=quality adjusted life year. *Maximum deviation from all correlation structures tested, which
occurred when all patients with hypertension were assumed to have diabetes and all patients with previous myocardial
infarction were assumed to also have previous stroke
Fig 2 Cost effectiveness acceptability curve for base case analysis. QALY=quality adjusted life year
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RESEARCHFig 3 Results of probabilistic sensitivity analysis on efficacy and safety end points, expressed as incremental QALYs. Values
are means and 95% central ranges from 2000 simulations. CHADS2= Congestive heart failure, Hypertension, Age≥75 years,
Diabetes mellitus, previous Stroke/transient ischaemic attack; CrCl=creatinine clearance; QALY=quality adjusted life year;
RE-LY= Randomized Evaluation of Long-Term Anticoagulation Therapy; TIA=transient ischaemic attack; TTR=time within
therapeutic range
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